Cash and cash equivalents and short-term investments were $263.7 million as of March 31, 2025. Annexon (ANNX) continues to expect its cash, cash equivalents and short-term investments as of March 31, 2025, to be sufficient to fund the company’s planned operating expenses and late-stage milestones for its lead programs into the second half of 2026.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences’ ANX005: Promising Phase III Results and Strategic Initiatives Drive Buy Rating
- Annexon announces tanruprubart trial meets primary endpoint
- Needham healthcare analysts hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks